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1. Introduction 
Kerr, Wyllie and Currie proposed a controlled cell elimination process, which acts 
complementary but opposite to cell division, to keep tissue homeostasis. That was suggested to be 
an active and programmed process which can be initiated or inhibited by various physiological or 
pathological stimuli. Since then, apoptosis as they termed, became a widely investigated cell 
physiological process. Later Horvitz et al. described the molecular genetic pathway responsible 
for apoptosis that leads to genetically determined cell elimination during the development of the 
model organism Caenorhabditis elegans. Apoptosis has become a widely used term and is often 
considered to be synonymous with programmed cell death (PCD), while necrosis remained a cell 
death type lacking the morphological signs of apoptosis. In the last decades accumulating 
evidences imply that necrotic cell death can also be a genetically regulated event and can be 
classified as programmed cell death in line with apoptosis. However, contrary to the fairly well 
characterized pathways of apoptosis the molecular constituents of necrotic pathway(s) are hardly 
known. 
Apoptosis, secondary necrosis and necroptosis 
Conventional knowledge considers apoptosis as a caspase-dependent, programmed, non-
immunogenic process, characterized by cellular shrinkage, membrane blebbing, chromatin 
condensation and DNA degradation. During apoptosis dying cell looses its contacts to the 
neighbouring cells and finally is fragmented into compact membrane-enclosed structures, called 
apoptotic bodies. Under normal physiological circumstances apoptotic bodies are engulfed by 
macrophages and are removed from the tissue without activating immune response.  
It is accepted that the main, but not obligate, hallmarks of apoptosis are the activation of caspases 
resulting in cleavage of a selective pool of proteins, the loss of phospholipid asymmetry of the 
plasma membrane, cell shrinkage and the early oligonucleosomal DNA fragmentation.  
In absence of corpse clearing mechanism the apoptotic process is terminated in an autolytic 
necrotic outcome, with loss of plasma membrane integrity. This phenomenon was called as 
secondary necrosis by Wyllie et al. with the intention to better distinguish this mode of cell 
elimination from “cellular necrosis occurring ab initio”, which should be called “primary 
necrosis”.  
Originally the word ne 
crosis was used as a pathological term which describes the morphology of dead cells observed in 
many human diseases such as neurodegenerative diseases as pancreas adiponecrosis, trauma, 
ischemia-reperfusion in myocardial infarction or in cerebral infarction, bacterial infection, tumor 
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malignancies and not as description characterising the way how cells dye. Morphologically, 
necrosis is marked by oncosis accompanied by early loss of the integrity of the plasma membrane 
and intracellular compartments.  
Accumulating evidences have confirmed that necrotic cell death can also be a regulated event and 
therefore be classified as programmed cell death in line with apoptosis.  
Necroptosis 
A novel, necrotic-like, caspase-independent cell death form has been recently described and 
termed as necroptosis. It was demonstrated that stimulation of the extrinsic apoptotic pathway by 
tumor necrosis factor-alpha (TNFα) or Fas ligand (FASL) under caspase-compromised conditions 
in certain cell types resulted in a necrotic-like cell death process. This pathway can be hampered 
by a small molecular weight inhibitor called necrostatin-1 (Nec), which acts by inhibiting the 
kinase activity of receptor-interacting protein kinase 1 (RIPK1) and by necrosulfonamide (NSA), 
an inhibitor of mixed lineage kinase domain-like protein (MLKL), a substrate of receptor-
interacting protein kinase 3 (RIPK3). It was shown that autophagy can be activated as 
downstream consequence of necroptosis. Moreover the role of poly(ADP-ribose) polimerase 
(PARP) was documented in RIPK-mediated necrosis. Here we use the term necroptosis a type of 
programmed necrosis which requires the kinase activity of RIPK1 and RIPK3 (receptor-
interacting protein kinase 1 and 3) and fulfills under caspase-compromised conditions.  
Former results 
Previously we studied the nature of the switch mechanism between apoptosis and necrosis and 
investigated the intrinsic apoptotic pathway in staurosporine (STS)-treated U937 cells. STS is a 
generally accepted inducer of the intrinsic apoptotic pathway and it is a wide spectrum inhibitor 
of protein kinases. STS initiates apoptosis by enhancing mitochondrial permeability transition. In 
the absence of clearing mechanism, the apoptotic cell death process is followed by secondary 
necrosis, an uncontrolled disruption of the plasma membrane. Earlier, we and others found that 
STS could provoke necrosis in caspase-compromised cancer cells. We were interested to examine 
the role of necroptosis in the same necrotic process, in spite of the fact that necroptosis is 
generally defined as a result of a death receptor-triggered cell death pathway. 
 2. Objectives 
Our aim was to characterize the molecular components of the STS-induced necrosis in U937 cell 
line. We were curious about the role of RIPK1, MLKL, PARP-1 and the effect of lysosomal 
enzyme inhibitor CA-074-OMe in STS-triggered necrosis to differentiate secondary necrosis and 
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necroptosis. We concomitantly established a TRAIL-induced necroptotic type of cell death model 
with U937 cells as a reference, death receptor-mediated necrosis. We intended to compare these 
two inducer (STS and TRAIL) evoked cell death mechanisms by using a panel of 
pharmacological inhibitors: caspase inhibitor: z-Val-DL-Asp-fluoromethylketone (zVD), PARP 
inhibitor: PJ-34, HSP90 inhibitor: geldanamycin (GA), PI3K (type III) inhibitor: 3-methyladenine 
(MA), cystein cathepsin inhibitor: CA-074-OMe (CA), RIP1K inhibitor: necrostatin-1 (Nec) and 
MLKL inhibitor: necrosulfonamide (NSA). 
3. Methods 
3. 1. Cell culture 
U937 promonocytic cells were cultured in RPMI 1640 medium, supplemented with 10 % heat 
inactivated fetal bovine serum, 2 mM L-glutamine and 100 μg/mL penicillin and 100 units/ml 
streptomycin at 37 oC in a 5% CO2 containing, humidified incubator. For treatments, cells were 
distributed into 48-well suspension plates at a cell density of 3 x 105 cells/mL or 5 x 105 cells/mL 
60 minutes before drug treatment. Then zVD (10 µM) was added with or without together other 
drugs as described above started 1 hr (Nec, CA, NSA, PJ) or 4 hrs (GA) before STS (1 µM) or 
TRAIL (50 ng/mL) addition. Duration of drug treatments varied between 4-24 hours. 
3. 2. Detection of the cell death-associated functional changes by flow cytometry  
Data collection was carried out by using FACScan or FACScalibur flow cytometers and analysis 
of the results was performed by WINLIST software.  
3. 2. 1. Assay of propidium iodide (PI) uptake of native cells representing the damage of 
plasma membrane 
Treated cells were stained directly by adding 0.5 mL PBS containing 5 mM glucose and 10 
μg/mL PI to each well. Cells were analyzed on FL2H log scale histograms.  
3. 2. 2. Characterization of phosphatidylserine distribution in the plasma membrane by 
flow cytometric analysis of Annexin V-FITC and PI double-labeled cells 
Cells were stained with PBS containing 5 mM glucose and 10 µg/mL PI for 10 minutes at 37 oC. 
After centrifugation, cells were suspended in binding buffer and stained with AnnexinV-FITC. 
Thereafter an additional 400 µL of binding buffer, containing 1 µg/mL PI was add to the samples 
and FACS analysis was carried out immediately.  
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3. 2. 3. Changes of mitochondrial transmembrane potential were characterized by the 
DiOC6(3) uptake method 
Treated cells were stained with PBS containing 5 mM glucose, 10 nM DiOC6(3) and 10 µg/mL 
PI and incubated further for 15 minutes at 37 oC and analyzed without further washing steps by 
FACS.  
3. 2. 4. Functioning lysosomal compartments are characterized by the red fluorescence of 
acridine orange (AO) emitted in the acidic environment of lysosomes 
Treated cells were stained with PBS containing 5 mM glucose and 5 µg/mL AO for 15 minutes at 
37 oC. The pelleted cells were resuspended in 1 mL of 5 mM glucose containing PBS and 
analyzed by FACS immediately.  
3. 2. 5. Determination of oligonucleosomal DNA fragmentation by the measurement of sub-
G1 population of cells 
Treated cells were pelleted and suspended in 70% ethanol. Then the ethanol-fixed cells were 
sedimented again and their oligonucleosomal sized DNA content were extracted by extraction 
buffer. The DNA remaining inside the permeabilized cells were stained with PI before FACS 
analysis.  
3. 2. 6. Representation of side scatter change and DNA fragmentation 
Treated cells were fixed, stained with PI and gated according to the sub-G1 technique. The gated 
populations were analyzed on the (SSC, FL2H) diagrams.  
3. 3. Agarose gel electrophoresis 
Samples were phenol-chloroform extracted once and their DNA content were precipitated in 
ethanol, pelleted and redissolved in TE buffer. DNA was electrophoresed in 1.5% agarose gel in 
TBA buffer, stained with ethidium bromide and DNA was detected under UV light. 
3. 4. Light microscopic studies 
Cytospin preparations were fixed in methanol, stained with hematoxylin-eosin, were dehydrated 
with ethanol, acetone and xilol. The morphological changes of apoptosis were studied by light 
microscopy at 400x magnification.  
3. 5. Fluorescent microscopic studies 
Treated U937 cells were pelleted and were stained with Hoechst dye and PI to distinguish 
between apoptotic and necrotic cells. After incubation cells were immediately photographed 
under a fluorescence microscope at 400x magnification.  
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3. 6. Western blot representation of PARP-1 and RIPK1 cleavage 
Cells were washed and resuspended in Laemmli buffer. After boiling, the samples were 
electrophoresed in a 10% SDS-PAGE gel and blotted onto nitrocellulose. After blocking 
membranes, specific antibodies against PARP-1, RIPK1 or GAPDH were added, incubated and 
membranes were washed. Blots were incubated with HPO-labeled second antibodies. Proteins 
were visualized by ECL.  
3. 7. Caspase activity assay 
Aliquots of cells were centrifuged and washed with PBS and finally were suspended in caspase 
buffer. After transferring samples into wells of 96-well plates, Triton X-100 was added and cell 
lysis was completed. Caspase substrate z-DEVD-AMC was admixed, and fluorescence intensities 
of the liberated amc were recorded in fluorescence plate reader. Excitation wavelength was 380 
nm and emission was measured at 445 nm.  
3. 8. Statistics 
Statistical analysis and significance of differences in comparable values were calculated by 
applying Student’s t-probe (two tailed, two sample unequal variance).  
4. Results 
4. 1. TRAIL induces necroptosis in U937 cell line in the presence of a caspase 
inhibitor 
We found U937 cells sensitive to TRAIL cytokine in 20 hrs. TRAIL treatment generated 
apoptotic nuclear DNA condensation together with nucleosomal DNA fragmentation. These 
changes resulted in apoptotic PARP-1 fragmentation due to caspase-3 activation. Finally, signs of 
secondary necrosis occurred when cells turn permeable for PI. 
When cells were pre-treated with the pan-caspase inhibitor zVD, the executioner caspase 
activation was prevented, therefore PARP-1 processing was inhibited. Apoptotic type 
oligonucleosomal DNA fragmentation diminished, however, the high molecular weight 
fragmentation of DNA appeared resembling necrosis and DNA condensation was evaded. Instead 
of apoptotic morphology, dying cells were swelling and showing a “ghost-like” morphology 
resembling necrosis. Plasma membrane rupture detected and quantified by PI uptake revealed 
that the number of PI positive cells in caspase inhibitor-sensitized U937 cells upon TRAIL 
treatment were increasing compared to cells treated with TRAIL alone. In the presence of RIPK1 
inhibitor Nec, PI uptake was reduced only marginally in caspase-competent (secondary necrotic) 
cells, while it was completely reduced in caspase-compromised cells after TRAIL treatment. 
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To further confirm the role of RIPK1 activity in TRAIL-induced necroptotic or secondary 
necrotic cell death processes we studied the effect of geldanamycin (GA). GA, an inhibitor of the 
heat shock protein 90 kDa (HSP90) was known to downregulate the protein level of RIPK1 and 
therefore was expected to halt necroptosis. Indeed, GA pre-treatment significantly reduced the 
extent of TRAIL-induced necroptosis detected by PI uptake.  
These results indicate that in the presence of caspase inhibitor, TRAIL-exposed U937 cells 
undergo necroptosis instead of apoptosis. Moreover TRAIL-triggered necroptosis can be 
suspended both by Nec and GA. 
4. 2. STS induces primary necrosis in the presence of a caspase inhibitor 
To study the STS-evoked necrosis we applied the caspase inhibitor zVD-fmk. We found that in 
the presence of zVD, DEVDase activity was completely halted and STS triggered mainly plasma 
membrane damage after shorter incubation time (8-12 hrs) meanwhile we could detect both sub-
G1 and PI-positive population after prolonged treatment (20 hrs).  
Next we tested the effect of the RIPK1 inhibitor under caspase-compromised conditions. Nec 
concentration dependently abrogated the necrosis confirmed by the reduced ratio of PI positive 
cells. Nec and GA arrested the necrosis after 8, 12 hrs of incubation time confirmed by flow 
cytometry and by fluorescent microscopic studies using Hoechst dye and PI double staining 
technique.  
After prolonged (20 hrs) treatment, the STS and zVD-triggered plasma membrane rupture was 
diminished only partially by Nec (~50%). Furthermore, Nec unaffected the caspase-mediated 
DNA fragmentation and condensation either after shorter (8, 12 hrs) or after longer incubation 
time (20 hrs). The STS-induced secondary necrosis, the final stage of cell death, was affected by 
neither Nec nor GA.   
Concerning the apoptotic parameters, STS and zVD-exposed samples showed high molecular 
weight DNA fragments confirmed by agarose gel electrophoresis, accompanied with low 
molecular weight DNA fragments that are primarily smear-like, opposite to apoptotic DNA 
fragmentation and typical to necrosis. STS treatment resulted in nucleosomal DNA ladder 
fragmentation trimmed possibly by postmortem DNase activity. 
These results indicate that STS-induced apoptosis in U937 cells ensued by secondary necrosis, 
while under caspase-compromised conditions STS induced primary necrosis that is partially 
inhibitable by Nec and GA, two drugs affecting RIPK1 activity. 
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4. 3. STS and TRAIL induce RIPK1 and MLKL-dependent necroptosis 
To confirm the role of RIPK1 in the STS-induced necroptosis, we tested the proteolytic 
degradation of RIPK1 in U937 cell line by Western blot analysis. STS-triggered caspase 
activation led to RIPK1 processing. Full length RIPK1 was proteolytically cleaved by caspase-8 
during STS-induced apoptosis. Processing of RIPK1 was highly inhibited in the presence of the 
caspase inhibitor zVD. 
To further study the molecular components involved in STS-triggered necroptotic pathway under 
caspase-compromised conditions we investigated the role of MLKL. Cells were treated with 
various concentrations of necrosulfonamide (NSA), an inhibitor of MLKL. NSA reduced the ratio 
of PI positive cells in a concentration-dependent fashion independently of the way of cell death 
trigger (either TRAIL or STS) under caspase-compromised condition. NSA arrested both the 
TRAIL and STS-triggered necrosis, confirmed by PI uptake measurements and also by 
Hoechst/PI double staining method. Meanwhile NSA failed to reverse the STS-evoked DNA 
fragmentation or prevent secondary necrosis.  
 These results confirmed the crucial role of RIPK1 and MLKL in STS and TRAIL-induced 
necrosis under caspase-compromised conditions. Therefore we can consider the observed 
necrosis in U937 cells as necroptosis. 
4. 4. MA reduces STS-induced necroptosis 
To test the contribution of autophagy to the STS-induced necroptotic process we studied the 
effect of 3-methyladenine (MA). MA is known to inhibit autophagy by blocking autophagosome 
formation via inhibition of type III phosphatidylinositol 3-kinases. We could detect only partial 
inhibition of MA either at 10 mM final concentration on STS+zVD-induced necroptosis, 
meanwhile MA was failed to adjust STS-triggered apoptotic pathway. In comparison to the effect 
of Nec, we also detected a partial protection of plasma membrane integrity under our standard 
assay conditions when MA was applied. The combination of Nec with MA resulted in an additive 
protection and no synergism was observed indicating that necroptosis and autophagic cell death 
are presumably two independent cell death pathways when cell death is induced by STS+zVD in 
U937 cells.  
4. 5. CA inhibits both the TRAIL and STS-induced necroptosis in the presence of a 
caspase inhibitor 
Previously we found that CA, an inhibitor of cysteine cathepsins, rescued the caspase-
independent necrotic form of cell death of promyelocytic leukemia cells treated by STS. In this 
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study we tested whether CA treatment might promote the survival of U937 cells dying under 
necroptotic conditions. 
Interestingly CA almost completely hampered the TRAIL-induced necroptotic cell death 
measured by plasma membrane rupture. Moreover, CA was comprehensive inhibitor of STS-
triggered necroptosis too. To further characterize the effect of CA on the necroptotic pathway and 
to compare to the inhibitory activities of Nec and GA, its action on different cellular 
compartments were investigated. Time course detection of mitochondrial membrane 
depolarization was carried out by flow cytometric analysis of DiOC6(3) stained STS+zVD-treated 
U937 cells. Our results confirmed that a continuous, time-dependent reduction of mitochondrial 
membrane integrity happens in the cell population. While Nec prevented partially the cells to 
loose their mitochondrial membrane potential for STS-treatment, CA provided nearly complete 
protection under caspase activity arrested conditions.  
In case of STS treatment, the effect of CA treatment on the reduction of phosphatidylserine 
translocation and plasma membrane rupture was complete. Similarly, the complete arrest of CA 
on the rupture of plasma membrane was detected by PI uptake and by Hoechst/PI double staining 
techniques for STS or TRAIL treated U937 cells in the presence of zVD. Moreover, the loss of 
lysosomal acidity induced either by STS or TRAIL treatment under necroptosis inducing 
conditions was remarkably withheld by CA pretreatment. Additionally CA could significantly 
prevent the loss of mitochondrial membrane depolarization in both cases of STS and TRAIL 
treatment in the presence of the caspase inhibitor zVD. 
The observed apoptotic parameters: the invariable percentage of the sub-G1 cell and the presence 
of ladder type DNA degradation observed in agarose gels proved that CA had no effect on 
caspase-dependent apoptosis or on the ensuing secondary necrosis in TRAIL or STS-exposed 
cells. Moreover, the absence of proteolytic degradation of RIPK1 also confirmed the avoidance 
of apoptosis.  
From these data we surmised that CA, similarly to NSA is also an effective inhibitor of the 
necroptotic pathway induced by STS in the presence of caspase inhibitor. While Nec and GA 
withheld only the early phase of STS-induced necroptosis in U937 cells. 
4. 6. PJ-34 does not arrest either the TRAIL or STS-induced necroptosis in the 
presence of a caspase inhibitor 
Participation of PARP-1 enzyme is well documented at several forms of cell death processes. 
Applying PARP inhibitor reduces the rate of PARP activation and slows down the exhaustion of 
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NAD and ATP pools, therefore generally shifts the cell death process towards apoptosis and 
prevents necrosis. 
In our experimental system we tested the effect of PARP-1 enzyme inhibitor PJ-34 on the 
necroptotic cell death pathway. Major differences in the necroptotic process were not observed in 
the presence of the inhibitor. In STS or in TRAIL-treated and caspase-inhibited U937 cells PJ-34 
did not influence the changes observed in mitochondrial transmembrane potentials, in PI 
permeability of cells, in the acidity of lysosomes or in the PS distribution in the plasma 
membrane. Furthermore, neither the caspase-dependent nor the caspase-independent STS or 
TRAIL-induced apoptotic DNA fragmentation was abolished by the applied PARP-1 inhibitor. 
At the same time the secondary necrotic cell death process was postponed by PJ-34 in a 
concentration-dependent manner. This effect was confirmed by the observed intact plasma 
membrane integrity both under STS and TRAIL-induced conditions where the enzyme activity of 
PARP-1 was increased in the absence of the inhibitor. In addition, the loss of lysosomal acidity 
was notably reduced by PJ-34 during prolonged treatment of U937 cells with STS and this effect, 
although with much less extent was observed after TRAIL treatment as well. 
Contrary to the necrotic process, in cases of STS or TRAIL-induced apoptosis PJ-34 showed only 
marginal effect on the cell death process. The hallmarks of apoptosis including 
phosphatidylserine distribution, loss of mitochondrial transmembrane and the DNA 
fragmentation were not influenced by PJ-34. These results indicate that PJ-34 could only delay 
the secondary necrosis, but was unable to prevent the caspase-dependent apoptosis. Our results 
show that the enzymatic activity of PARP-1 directly or indirectly influences the process of 
secondary necrosis but is dispensable in necroptosis at least in TRAIL and STS-treated U937 
cells. 
5. Conclusions  
1.) TRAIL, a death receptor ligand cytokine, which generally induces apoptotic cell death 
through the extrinsic pathway, under caspase-compromised conditions triggers necroptosis in 
U937 cells inhibitable by necrostatin, geldanamycin and necrosulfonamide. 
2.) Staurosporine, a kinase inhibitor compound which generally induces apoptosis through the 
intrinsic pathway can also induce necroptosis under caspase-deprived conditions inhibitable by 
necrostatin, geldanamycin and necrosulfonamide.  
3.) In parallel with the staurosporine-induced RIP-mediated necroptotic process, an autophagy-
like process is also activated, and shown to be partially blocked by the PI3K inhibitor MA. The 
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combination of necrostatin with 3-methyladenin resulted in an additive protection of cell death 
and no synergism was observed indicating that RIP-mediated necroptosis and autophagic-like cell 
death are presumably two parallel processes in U937 cells. 
5.) CA inhibits the necroptotic cell death in U937 cells induced by either TRAIL or 
staurosporine. Note that while the inhibitory potential of necrostatin and geldanamycin is only 
partial, CA-074-OMe treatment of cells provide complete protection upon staurosporine 
treatment. (These results point out that a non-cathepsin B, off-target of CA-074-OMe can be an 
initiator position of necroptosis.) 
6.) In U937 cells neither apoptosis nor necroptosis was influenced by PJ-34. On the other hand, 
while the secondary necrosis of U937 cells was significantly postponed by PJ-34, it was not 
affected by necrostatin, geldanamycin, necrosulfonamide or CA-074-OMe at all. (If these results 
will be proved in other cancer cell lines, clinical application of PARP inhibitors might control the 
tumor lysis syndrome). 
The flow chart shown here summarizes the hypothetic places of actions, where the drugs used in 
the current study inhibit the staurosporine or TRAIL-induced cell death pathways in U937 cells. 
We hope that the presented results will contribute to the better understanding of the molecular 
background of necroptosis. 
 
 
Schematic diagram of the action of inhibitors on TRAIL and staurosporine-induced cell 
death pathways in U937 cell line. 
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